Phytanix Bio, SPAC Company Chain Bridge I Enter Definitive Business Combination Agreement; Combined Company To Be Named Phytanix Inc.
Phytanix Bio, SPAC Company Chain Bridge I Enter Definitive Business Combination Agreement; Combined Company To Be Named Phytanix Inc.
Phytanix Bio、SPAC公司Chain Bridge I签署最终业务合并协议；合并后的公司将命名为Phytanix Inc。
Upon closing of the transaction, expected to occur in the fourth quarter of 2024, the combined company will be named Phytanix Inc., and its common stock is expected to be listed on the Nasdaq Capital Market under the ticker symbol "PHYX."
预计交易将于2024年第四季度完成，合并后的公司将命名为Phytanix Inc.，其普通股预计将在纳斯达克资本市场上以“PHYX”作为逐笔明细标的上市。
Phytanix is pioneering a new and innovative approach in the development of cannabinoid and cannabinoid-like medicines.
Phytanix正在开发新型创新药物，以大麻素和类大麻素为基础。
The transaction reflects a pre-deal valuation of $58 million for Phytanix Bio plus the assumption of $17 million of preferred stock and $4.4 million of short-term debt that will be exchanged for convertible preferred stock at deal close
该交易反映了Phytanix Bio 5800万美元的预交易估值，以及承担的1700万美元优先股和440万美元短期债务，这将在交易结束时转换为可转换优先股。
资讯热榜
更新时间